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Evidence-based Investigations 
for Subfertility 
Joyce Chai, MBChB, MRCOG, FHKAM; Ernest Hung Yu Ng, MBBS, MD, FRCOG, FHKAM
Subfertility is a worldwide problem – 72.4 million couples are estimated to have fertility 
problems globally.
INTRODUCTION
According to the World Health Organiza-
tion (WHO), subfertility is ‘a disease of the 
reroductiÈe syste deoned by the fail-
ure to achieve a clinical pregnancy after 
12 months or more of regular unprotect-
ed sexual intercourse’.1 The prevalence 
of subfertility varies widely depending on 
the deonition used,2 but undoubtedly it 
is a global problem of which nearly 72.4 
million couples are estimated to have 
fertility problems.3 The consequences of 
subfertility are manifold and can include 
psychological and social impact on the 
individuals as well as the cost burden on 
the health care system.  
Evaluation of the subfertile couple 
should therefore be conducted in a 
systematic, expeditious, and cost-
effective manner to identify all relevant 
factors, with initial emphasis on the 
least invasive methods for detection of 
the most common causes of infertility.4 
Approximately 84% percent of couples 
conceive within 1 year of trying, and 
about 92% do so within 2 years.5 
It is recommended that subfertility 
evaluation should be initiated after 1 
year of attempted conception in women 
under age 35, and earlier evaluation is 
warranted in women over age 35 years 
or women with oligo-/amenorrhoea or 
known risk factors for infertility, such 
as endometriosis, a history of pelvic 
inqammatory disease, or reproductive 
tract malformations.
There are multiple causes of 
subfertility and most are related to 
ovulatory disorders, tubal damage, 
uterine or peritoneal disorders, 
endometriosis, and factors in the male 
causing infertility. In about 25% of 
cases the cause is unexplained in view 
of normal semen analysis, ovulation 
and patent tubes, and in nearly 40% of 
infertile couples, both the man and the 
woman are affected.  It is therefore of 
paramount importance that the couples 
are evaluated together and separately, 
with the aim to establish presence of 
subfertility, to determine the underlying 
cause and to provide appropriate 
counseling and treatment accordingly.6  
INITIAL ASSESSMENT
Initial consultation with the subfertile 
couple should include a complete medi-
cal and reproductive history and physical 
examination, preconception counseling, 
and instruction on the optimization of in-
1 POINT
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tercourse.  A summary of the history and 
examination of an infertile couple is given 
in Table 1.  
For all women seeking fertility, 
susceptibility to rubella should be 
checked.  Maternal rubella infection in 
the orst trimester of pregnancy can result 
in severe congenital fetal abnormalities7 
and it is easily preventable by pre-
conception vaccination. Screening for 
populations at risk for specioc inheritable 
diseases should be performed. 
Thalassaemia is one of the world’s most 
common single-gene disorders, and 
prevalence is especially high in Asia, 
Middle East, and Mediterranean region. 
Women at risk should have their mean 
corpuscular volume (MCV) checked as 
a screening test. If a woman is found to 
be a genetic carrier, the male partner 
should also be offered testing. Up-to-
Table 1.  Focused history and examination of the couple
Female Male
History Fertility history
• Previous pregnancies and outcomes
• Duration of infertility
• Previous investigations/treatment
Menstrual history
• Cycle regularity
• Dysmenorrhoea
Medical history
• Systemic illness
• Medications/on folic acid
• Genetic disease
Gynaecological history
• Pelvic inﬂammatory disease
• Sexually transmitted disease
• Endometriosis/dyspareunia
• Previous contraception
• Cervical smears
Surgical history
• Complicated appendicitis
• Ovarian cystectomy
Social history
• Smoking/alcohol
• Recreational drugs
Fertility history
• Previous pregnancies
• Duration of infertility 
• Puberty onset
Medical history
• Systemic illness – diabetes
• Genetic disease
• History of mumps
• Sexually transmitted disease
• Medications
Surgical history
• Orchidopexy, cryptorchidism
• Testicular torsion
Sexual history
• Erections/ejaculations
• Frequency of intercourse
Social history
• Smoking/alcohol
• Recreational drugs
Occupation
Examination Body mass index
Thyroid and breast examination
Secondary sexual characteristics
Presence of hirsutism
Pelvic examination and examination of vagina 
and cervix
Determination of uterine size, shape and 
mobility
Check for adnexal masses, tenderness or 
nodularity
Body mass index
Secondary sexual characteristics
If abnormal SA: 
Palpation and measurement of testes
Presence of vas 
Examination of epididymides
Check for varicocoele
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date cervical smear of the women should 
also be ensured.
INVESTIGATIONS
Evaluations of Male Subfertility 
Semen Analysis
A male factor is solely responsible in 
approximately 20% of subfertile cou-
ples and contributes in another 30-40% 
of couples.8 Semen analysis (SA) is the 
cornerstone of the evaluation following 
history taking and physical examination, 
and it helps to deone the severity of the 
male factor. A minimum of at least one 
semen sample should be collected for 
evaluation after an abstinence interval 
of 2 to 5 days. A longer period of ab-
stinence can lead to reduced motility 
in normospermic samples.9 The semen 
sample provides information on semen 
volume as well as sperm concentration, 
motility, and morphology, and the anal-
ysis should be performed according to 
WHO criteria.10 The reference values are 
listed in Table 2, and each laboratory 
should have a quality control program 
that conforms to the standards.  
Assessment for the presence of 
autoimmune anti-sperm antibodies 
should no longer be the standard part 
of SA because the signiocance of its 
presence is unclear and there is no 
effective treatment in terms of improving 
male fertility.5 Limitations of SA include 
individual quctuations and a substantial 
overlap between fertile and subfertile 
values.11 A repeat semen analysis should 
be performed, ideally at least 3 months 
after the initial sample, if the result of the 
orst analysis is abnormal.5 If azoospermia 
or severe oligospermia is reported in 
the initial SA, a repeat test should be 
undertaken within 2 to 4 weeks.  
Routine use of specialized clinical 
tests on semen and sperm including 
sperm function tests, computer-
assisted seminal analysis, and sperm 
DNA fragmentation tests in the clinical 
evaluation of male factor infertility is 
currently not recommended.5,12 Although 
sperm DNA damage may associate with 
poor reproductive performance, current 
methods for assessing sperm DNA 
integrity do not reliably predict treatment 
outcomes. Sperm function tests also 
vary in their ability to detect defects 
in the complex processes leading to 
fertilization, and therefore are of limited 
use from a practical point of view. These 
tests should be reserved as research 
tools rather than as routine clinical tests. 
Additional Testing
If hypogonadism is suspected based 
on the SA (severe oligospermia with 
sperm concentration below 10 million/
mL or azoospermia), evaluation of se-
rum follicle-stimulating hormone (FSH) 
and total testosterone concentrations is 
indicated.13 If severe oligospermia (<5 
million/mL) is found and the physical 
examination does not reveal signs of ob-
struction, the American Society for Re-
productive Medicine (ASRM) suggested 
a genetic workup as the prevalence of 
chromosomal abnormalities is inversely 
proportional to sperm count.14,15 Howev-
er, in Hong Kong, the prevalence rates 
of chromosomal abnormalities and Y-mi-
crodeletions were only 1.5% in men with 
sperm concentration >2 and <5 million/
mL compared to 13.9% in men with 
sperm concentration >0 and )2 million/
mL; hence genetic workup is only rec-
ommended in infertile men with sperm 
concentrations of 2 million/mL or lower.16 
A thorough evaluation by an 
urologist or reproductive endocrinologist 
is warranted for men with abnormal 
semen parameters, physical examination 
or endocrine/genetic proole.
Evaluation of female subfertility 
Assessment of Ovulation
Pregnancy is the ultimate test of normal 
ovulation, but it only occurs in around 
25% of cycles in women who have in-
tercourse during the peri-ovulatory pe-
riod.17 Ovulatory disorders account for 
up to 25% of subfertility causes, and it is 
usually reqected in menstrual irregulari-
ties, typically cycles of long duration or 
complete absence of cycles. Common 
Table 2. World Health Organization semen analysis reference values
Parameter Lower reference limit
Semen volume
Sperm concentration
Total sperm number
Progress motility
Total motility
Sperm morphology
1.5 mL
15 million 
39 million 
32% 
40%
4% 
A male factor is solely responsible in 
approximately 20% of subfertile couples and 
contributes in another 30-40% of couples
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causes of ovulatory disorders are listed 
in Table 3.  Regular menstrual cycles 
in the range of 22 to 35 days are usu-
ally indicative of ovulation, as does the 
presence of premenstrual symptoms.18 
However, conormation with mid-luteal 
(day 21 of a 28-day cycle) serum proges-
terone is recommended for women with 
regular menstrual cycles and more than 
1 year’s infertility.5 Values range from 16-
28 nmol/L as the lowest limit indicative 
of ovulation.  For women with irregular 
cycles, this test may need to be done lat-
er in the cycle and repeated weekly until 
the next menstrual period. 
Testing in women with amenorrhoea 
or oligomenorrhoea should also involve 
FSH, prolactin, and thyroid-stimulating 
hormone (TSH) levels, to help determine 
the underlying cause of anovulation. 
In asymptomatic women with regular 
cycles, these hormones should not be 
checked routinely. Pelvic ultrasound 
will be performed for polycystic ovary 
morphology. 
In ovulatory cycles, morning basal 
body temperature (BBT) often increases 
as the cycle progresses from the follicular 
phase to the luteal phase, giving the 
biphasic BBT recordings. However, not 
all women with ovulatory cycles will have 
clearly documented biphasic BBT.19 
Although BBT charting is a simple and 
inexpensive means of documenting 
ovulation, it does not reliably predict 
ovulation20 and is therefore not 
recommended.5 In recent years, women 
have largely replaced BBT charting by 
the less tedious, more easily available 
urinary luteinizing hormone (LH) kit 
to detect ovulation. During ovulatory 
cycles, an LH surge can be detected in 
the urine 14-48 hours before ovulation.21 
Urinary LH kits can accurately predict 
ovulation,22 but reliability can be variable 
among different commercial kits23 and 
one should be aware of potential false-
positive and false-negative results 
when interpreting. Daily serum LH 
measurements to detect LH surge is 
considered impractical in clinical setting. 
Monitoring the daily growth of the 
pre-ovulatory follicle by pelvic ultrasound 
and eventually the demonstration of 
collapse of the growing follicle and 
appearance of quid in cul-de-sac 
indicates ovulation. Due to the labour 
intensive nature and high cost, this is 
not considered the preferred method of 
ovulation detection.  
Assessment of Tubal Patency
Different screening strategies are avail-
able in assessing tubal patency and di-
agnosing tubal subfertility, and the ones 
that have been studied and used widely 
include laparoscopy with chromotuba-
tion, hysterosalpingography, hyster-
osalpingo-contrast sonography, and 
chlamydial serology. More sophisticated 
tests like transvaginal hydrolaparoscopy, 
salpingoscopy, falloposcopy and fertilo-
scopy require special expertise and their 
diagnostic accuracy and prognostic 
ability require further evaluation.  Each 
diagnostic test has its own beneots and 
limitations and therefore the selection of 
a particular test should be individualized. 
Invasive tubal patency test should only 
be offered after taking into account the 
overall treatment needs of the women, 
Table 3. Common causes of ovulation disorders
Hypogonadotrophic hypogonadism
• Idiopathic 
• Kallmann’s syndrome
• Excessive weight loss, exercise, stress, drugs
• Pituitary tumour, pituitary necrosis or thrombosis
Normogonadotrophic normogonadic ovarian dysfunction
• Polycystic ovary syndrome
Hypergonadotrophic hypogonadism
• Genetic, Turner’s syndrome
• Autoimmune 
• Surgical menopause, post radiotherapy/chemotherapy
• Idiopathic
Other endocrinopathies
• Hyperprolactinaemia
• Thyroid dysfunction
• Androgen excess 
Ovulatory disorders account for up to 25% of 
subfertility causes, and it is usually reqected in 
menstrual irregularities, typically cycles of long 
duration or complete absence of cycles.
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and testing can be avoided in those who 
require in vitro fertilization (IVF) treatment 
regardless.
Genital chlamydia trachomatis 
infection is recognized as the single 
most common cause of tubal peritoneal 
damage,24 and therefore chlamydia 
serology has been used as a screening 
test for tubal damage in infertile women. 
The sensitivity and speciocity of C 
trachomatis antibody test (CAT) varies 
depending on the assays used and the 
cut-off value used to deone a positive 
result.25 It should not be regarded as 
a diagnostic test but as a screening 
test to facilitate decisions on which 
women should proceed with further 
investigations. 
Hysterosalpingography (HSG) 
refers to the radiographic evaluation of 
the uterine cavity and fallopian tubes 
after injection of a radio-opaque medium 
through the cervix.  It is widely available 
and provides information about tubal 
patency, site of occlusion, outline of 
the lumen, as well as the contour of the 
uterine cavity. In addition, a therapeutic 
beneot has been observed with the use 
of oil-soluble contrast medium when 
compared to no intervention and water-
soluble contrast medium,26 possibly 
related to the qushing of debris from the 
tubal lumen. HSG has sensitivity and 
speciocity of 53% and 87% respectively,27 
and the moderate sensitivity is likely 
related to tubal spasm during dye 
injection and intra-observer variability. 
It should be offered as orst line tubal 
investigation for subfertile women with 
no risk factors,5 after explaining to them 
the risk of pelvic infection, anaphylaxis 
and radiation exposure.
Hysterosalpingo-contrast sonog-
raphy (HyCoSy) is an alternative imag-
ing technique to the HSG. It involves 
transvaginal ultrasound and injection of 
sonographic contrast medium into the 
uterine cavity. It has the advantage over 
HSG of simultaneous examination of the 
ovaries and myometrium, and avoidance 
of radiation exposure. A recent system-
atic review and meta-analysis showed 
that HyCoSy had similar sensitivity and 
speciocity as HSG when compared to 
diagnostic laparoscopy.28 Where appro-
priate expertise is available, HyCoSy can 
be considered as an effective alternative 
to HSG.5
Diagnostic laparoscopy with 
chromotubation (injection of a blue dye 
In recent years, urinary luteinizing hormone (LH) test kits have largely replaced more tedious, less accessible methods of assessment of 
female ovulation.
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through the cervix and visualization of 
spillage out of the ombrial end of the 
tubes) is considered to be the gold-
standard test for tubal patency. It offers 
the additional beneots of assessing the 
whole pelvis and opportunistic treatment 
of possible pathologies like minimal/mild 
endometriosis and peri-tubal adhesions 
will provide some therapeutic beneots.29 
However, given its invasiveness and 
requirement for general anaesthesia, 
it should not be routinely offered 
but only to those with inconclusive/
abnormal HSG result and/or risk factors 
which include history of complicated 
appendicitis, pelvic surgery, ectopic 
pregnancy, pelvic inqammatory disease, 
and endometriosis.5,30
Uterine Factor Evaluation
Uterine cavity abnormalities such as ad-
hesions, endometrial polyps, submucosal 
obroids and uterine septum have been 
found in 10-15% of women seeking treat-
ment for fertility problems.31 However, the 
causal relationship between these uterine 
abnormalities and subfertility has not been 
properly established. Ultrasonography for 
uterine evaluation is therefore not a man-
datory investigation, although many clini-
cians perform scans routinely nowadays 
due to its easy access and wide availabili-
ty. Any suspicious ondings on ultrasonog-
raphy will require further evaluation with 
saline infusion sonohysterography or hys-
teroscopy, but these invasive tests should 
not be considered as a routine investiga-
tion. Currently, insufocient evidence exists 
to support routine surgical treatment of 
uterine abnormalities in improving preg-
nancy rates.32 
In the past, endometrial biopsy had 
been a routine part of the fertility evaluation 
to check for ovulation and luteal phase 
defect by “dating” the endometrium using 
traditional histologic criteria.33 However 
subsequent studies have not proved this 
test to be a useful discriminator between 
fertile and infertile populations,34 and it 
is no longer a recommended part of the 
infertility evaluation.4,5
Cervical Factor Evaluation
The presence of motile sperm in perio-
vulatory cervical mucus on postcoital 
A detailed and focused history examination of a couple affected by fertility problems will aid initial investigations and treatment.
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test (PCT) was the traditional method for 
diagnosis of cervical factor subfertility. 
However this test has poor diagnostic 
potential and predictive value.35 Moreo-
ver, a randomized controlled trial com-
paring the outcome of subfertility investi-
gations with and without PCT showed no 
difference in cumulative pregnancy rate 
at 24 months.36 These limitations have 
render PCT unnecessary for subfertility 
evaluation.4,5
Ovarian Reserve Evaluation
Ovarian reserve, the size of the oocyte 
pool, reqects the reproductive potential 
of a woman and it is closely associat-
ed with female age, which is the sin-
gle most important factor inquencing 
reproductive outcome. Tests utilized 
to assess ovarian reserve include cycle 
day 3 FSH, an early follicular phase an-
tral follicle count via transvaginal ultra-
sonography, or a serum anti-mullerian 
hormone (AMH) level.4 Unfortunately 
none of these tests is reliable for pre-
dicting pregnancy potential in IVF treat-
ment or in spontaneous pregnancy.37,38  
Ovarian reserve tests do not establish 
a diagnosis of subfertility, and tests 
should only be done prior to assisted 
reproductive technology (ART) treat-
ment to predict the likely ovarian re-
sponse to stimulation with exogenous 
gonadotropins.  
 CONCLUSION
Subfertility is a common condition af-
qicting couples, and both partners 
should be evaluated promptly once the 
diagnosis of subfertility has been estab-
lished. A detailed and focused history 
and examination of the couple will help 
facilitate initial investigations and treat-
ment. The basic subfertility evaluation 
consists of semen analysis, assessment 
of ovulatory status, and determination 
of tubal patency.  Additional testing be-
yond these basics should be pursued 
only when clinically indicated or for re-
search purposes. 
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